Xilio Therapeutics financials
$8.94−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M | $12.6M | $13.7M | $19.1M | $8.1M | $2.9M | $1.7M | $2.3M | $2.4M | $0.00 | $0.00 | $0.00 |
| Gross profit | $18.7M | $12.6M | $13.7M | $19.1M | $8.1M | $2.9M | $1.7M | $2.3M | $2.4M | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$3.5M | -$14.1M | -$11.8M | -$1.9M | -$14.4M | -$13.9M | -$13.6M | -$14.8M | -$14.7M | -$17.5M | -$18.1M | -$17.4M |
| Net income | -$6.4M | -$9.5M | $10.4M | -$16.3M | -$15.8M | -$13.3M | -$13.1M | -$14.0M | -$13.9M | -$17.2M | -$17.7M | -$16.7M |
| Net margin | −34.1% | −75.3% | 75.7% | −85.4% | −196.0% | −452.7% | −759.5% | −619.5% | −590.8% | — | — | — |
| Diluted EPS | $-0.33 | $-0.58 | — | $-1.54 | $-2.30 | $-2.49 | $-2.82 | $-3.08 | $-3.36 | $-8.68 | $-8.97 | $-8.54 |
| EBITDA | -$3.2M | -$13.8M | -$11.5M | -$1.6M | -$14.0M | -$13.4M | -$13.6M | -$14.4M | -$14.2M | -$16.1M | -$17.7M | -$16.9M |
| Operating cash flow | -$18.8M | -$22.3M | -$2.0M | -$17.5M | -$14.5M | $29.0M | -$14.2M | -$13.7M | $20.0M | -$10.5M | -$13.4M | -$13.4M |
| Free cash flow | -$18.8M | -$22.9M | -$2.1M | -$17.5M | -$14.9M | $29.0M | -$14.2M | -$13.7M | $19.9M | -$10.5M | -$13.4M | -$13.4M |
| Diluted shares | 19.4M | 16.3M | — | 10.3M | 6.9M | 5.3M | 4.6M | 4.5M | 4.1M | 2.0M | 2.0M | 2.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $136.0M | $150.3M | $137.5M | $103.8M | $121.6M | $89.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $154.3M | $163.5M | $154.7M | $133.7M | $133.8M | $103.7M |
| Total liabilities | $82.0M | $90.9M | $119.4M | $141.8M | $126.7M | $93.0M |
| Shareholders' equity | $72.3M | $72.5M | $35.3M | -$8.1M | $7.1M | $10.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology